Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19776245 | 0.95 | KCNH2 (0.35) | KCNH2SSTR4ALDH1A1 | |
| SCHEMBL28724510 | 0.86 | KCNH2 (0.32) | KCNH2SSTR4ALDH1A1 | |
| SCHEMBL22684294 | 0.85 | KCNH2 (0.35) | KCNH2SSTR4NR1D1 | |
| SCHEMBL19782960 | 0.83 | MAPT (0.33) | KCNH2SSTR4ALDH1A1NR1D1NR1H3 | |
| SCHEMBL21874611 | 0.80 | LMNA (0.32) | ALDH1A1CYP1A2CYP2D6CYP2C19NR1D1 | |
| SCHEMBL30039558 | 0.80 | KCNH2 (0.36) | KCNH2SSTR4ALDH1A1 | |
| SCHEMBL28458792 | 0.80 | KCNH2 (0.36) | KCNH2SSTR4ALDH1A1 | |
| SCHEMBL21459869 | 0.78 | LMNA (0.37) | KCNH2ALDH1A1NR1D1NR1H3 | |
| SCHEMBL30059621 | 0.76 | SSTR4 (0.39) | KCNH2SSTR4ALDH1A1NR1D1 | |
| SCHEMBL23013905 | 0.75 | PTGER4 (0.34) | KCNH2ALDH1A1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315774-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315774-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, PF4 | KCNH2 2715/4885SSTR4 392/4885ALDH1A1 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.